Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Taysha Gene Therapies Inc

Healthcare US TSHA

5.89USD
0.34(6.13%)

Last update at 2026-06-04T20:00:00Z

Day Range

5.555.94
LowHigh

52 Week Range

0.503.89
LowHigh

Fundamentals

  • Previous Close 5.55
  • Market Cap607.81M
  • Volume2280341
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-70.00300M
  • Revenue TTM15.45M
  • Revenue Per Share TTM0.13
  • Gross Profit TTM 2.50M
  • Diluted EPS TTM-0.78

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -166.01400M -174.52300M -60.01100M -
Minority interest - - - -
Net income -169.58100M -175.45900M -43.00000M -
Selling general administrative 37.36M 41.32M 11.11M -
Selling and marketing expenses - - - -
Gross profit 2.50M - - -
Reconciled depreciation 1.17M 0.49M 0.00900M -
Ebit -162.44700M -173.26700M -43.00200M -4.46000M
Ebitda -125.79600M -173.09500M -59.98300M -
Depreciation and amortization 36.65M 0.17M -16.98100M -
Non operating income net other - - -17.03000M -
Operating income -162.44700M -173.26700M -43.00200M -
Other operating expenses 128.53M 173.27M 43.00M -
Interest expense 3.80M 1.43M 0.03M 0.00000M
Tax provision - - - -
Interest income 0.25M 0.17M 0.05M -
Net interest income -3.54900M -1.25600M 0.02M -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 3.57M 0.94M -17.01100M -
Total revenue 2.50M 0.00000M 0.00000M -
Total operating expenses 128.53M 173.27M 43.00M -
Cost of revenue - - - -
Total other income expense net -3.56700M -1.25600M -17.00900M -
Discontinued operations - - - -
Net income from continuing ops -166.01400M -174.52300M -60.01100M -
Net income applicable to common shares - -174.52300M -60.01100M -4.46000M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 266.99M 126.28M 213.96M 258.88M 0.01M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.80M 8.54M 10.50M 6.63M 0.01M
Total liab 192.06M 125.33M 118.57M 7.58M 0.15M
Total stockholder equity 74.94M 0.95M 95.38M 251.30M -0.13500M
Deferred long term liab - - - - -
Other current liab 10.64M 16.77M 29.98M 5.13M 0.15M
Common stock 0.00200M 0.00100M - - -
Capital stock 0.00200M 0.00100M 0.00000M 0.00000M 0.00000M
Retained earnings -513.00700M -401.44100M -235.64900M -61.12600M -1.11500M
Other liab - 4.13M 3.73M 0.45M -
Good will - - - - -
Other assets - 3.95M 3.74M 0.71M -
Cash 144.39M 87.88M 149.10M 251.25M -
Cash and equivalents - - - - -
Total current liabilities 36.76M 62.79M 51.75M 7.13M 0.15M
Current deferred revenue 18.11M 33.56M - - -
Net debt -83.28200M -27.95200M -86.01100M -251.25300M -
Short term debt 1.65M 1.52M - - -
Short long term debt - - - - -
Short long term debt total 61.11M 59.93M 63.09M - -
Other stockholder equity 587.94M 402.39M 331.03M 312.43M 0.98M
Property plant equipment - - 50.61M 0.29M -
Total current assets 149.19M 96.42M 159.60M 251.25M 0.01M
Long term investments - - - - -
Net tangible assets - - 95.38M 251.30M -0.13500M
Short term investments - - - - -
Net receivables - - - - -
Long term debt 40.51M 37.97M 37.19M - -
Inventory - - - - -
Accounts payable 6.37M 10.95M 21.76M 1.99M -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - -61.12600M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.98M 3.95M 3.74M 7.34M -
Deferred long term asset charges - - - - -
Non current assets total 117.81M 29.86M 54.35M 7.63M 0.00000M
Capital lease obligations 20.60M 21.96M 25.90M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -24.93000M -21.55400M -9.08200M -
Change to liabilities 33.56M 14.49M 1.96M 0.00000M
Total cashflows from investing activities -24.93000M -21.55400M -9.08200M -9.08200M
Net borrowings - 39.96M 39.96M 39.96M
Total cash from financing activities 52.10M 39.08M 291.06M 291.06M
Change to operating activities -7.23500M 14.17M -2.07200M 0.54M
Net income -166.01400M -174.52300M -60.01100M -4.46000M
Change in cash -61.22300M -99.51300M 251.25M 251.25M
Begin period cash flow 151.74M 251.25M 0.00000M -
End period cash flow 90.52M 151.74M 251.25M -
Total cash from operating activities -88.39000M -117.04200M -30.72900M -30.72900M
Issuance of capital stock 53.24M 0.00000M 291.06M -
Depreciation 1.17M 0.49M 0.00900M 0.00900M
Other cashflows from investing activities -0.06100M -0.06100M -9.00000M -0.06100M
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock - - 291.06M -
Other cashflows from financing activities -1.14700M 39.08M 126.88M -0.79000M
Change to netincome 57.93M 28.32M 29.38M 3.92M
Capital expenditures 24.87M 21.55M 9.08M 0.08M
Change receivables - - - -
Cash flows other operating - - 14.96M -
Exchange rate changes - - - -
Cash and cash equivalents changes - - 251.25M -
Change in working capital 18.52M 28.67M -0.11100M -
Stock based compensation 18.04M 18.18M 3.35M -
Other non cash items 39.89M 10.14M 26.03M -
Free cash flow -113.25900M -138.59600M -39.81100M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TSHA
Taysha Gene Therapies Inc		 0.34 6.13% 5.89 - - 35.59 7.33 30.16 -4.4304
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Taysha Gene Therapies Inc

3000 Pegasus Park Drive, Dallas, TX, United States, 75247

Key Executives

Name Title Year Born
Mr. R. A. Session II Founder, Pres, CEO & Director 1979
Mr. Kamran Alam CPA, M.B.A. Chief Financial Officer 1978
Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M Chief Medical Officer and Head of R&D 1970
Mr. Frederick Porter Ph.D. Chief Technical Officer NA
Mr. Jim Rouse Chief Information Officer NA
Ms. Tracy M. Porter Chief People Officer NA
Ms. Emily McGinnis M.P.H. Chief Patient Officer & Head of Gov. Affairs NA
Ms. Mishima Gerhart Chief Regulatory Officer & Head of Quality NA
Mr. Sean McAuliffe Chief Commercial Officer NA
Mr. Greg Gara Sr. VP of Manufacturing NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions